- ICH GCP
- EU 임상 시험 레지스트리
최신 시험
EudraCT Number: 2004-004153-25 | Sponsor Protocol Number: JIA6 | Start Date: 2004-12-10 | ||||||
Sponsor Name: Royal Hospital For Sick Children, Yorkhill Division | ||||||||
Full Title: Effect of recombinant growth hormone on growth and chondrocyte dynamics in children with juvenile idiopathic arthritis (JIA) and growth failure. | ||||||||
Medical condition: Growth retardation secondary to juvenile idiopathic arthritis | ||||||||
|
||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||
Trial protocol: GB (Prematurely Ended) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001363-22 | Sponsor Protocol Number: TH-CR-302 | Start Date: 2004-12-10 | |||||||||||
Sponsor Name: Threshold Pharmaceuticals | |||||||||||||
Full Title: A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared with Best Supportive Care in Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine | |||||||||||||
Medical condition: Previously treated metastatic pancreatic adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002821-30 | Sponsor Protocol Number: 12 | Start Date: 2004-12-09 | |||||||||||
Sponsor Name: Institute of Oncology, Vilnius University | |||||||||||||
Full Title: Study of the efficacy of intravesical instillations of interleukin-2 in treatment of superficial bladder cancer | |||||||||||||
Medical condition: Ta,T1 /G1,G2,G3 superficial bladder cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-004010-17 | Sponsor Protocol Number: ANG206 | Start Date: 2004-12-09 | ||||||
Sponsor Name: Amersham plc and its Amersham Health affiliates, trading as GE Healthcare | ||||||||
Full Title: An open-label, multi-centre, phase 2a study to assess the feasibility and safety of intravenous bolus administration of 99mTc-NC100692 Injection in imaging metastases in late stage cancer patients. | ||||||||
Medical condition: The subjects to be included in this study have been diagnosed with primary breast, lung (non-small cell), ovarian or prostate cancer or malignant melanoma and have metastatic spread of the cancer t... | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: SE (Prematurely Ended) GB (Completed) DE (Completed) ES (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2004-003887-31 | Sponsor Protocol Number: 2004/116 | Start Date: 2004-12-09 | ||||||
Sponsor Name: Klinisk Farmakologisk Center og Med. Afd. M, Århus Sygehus, NBG | ||||||||
Full Title: "Farmakodynamiske egenskaber af to langtidsvirkende insulinanaloger i sammenligning med NPH insulin" | ||||||||
Medical condition: Healthy subjects. | ||||||||
|
||||||||
Population Age: Adults | Gender: Male | |||||||
Trial protocol: DK (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000654-23 | Sponsor Protocol Number: EORTC 18032 | Start Date: 2004-12-09 | |||||||||||
Sponsor Name: EORTC | |||||||||||||
Full Title: Extended schedule, escalated dose Temozolomide versus Dacarbazine in Stage IV Metastatic Melanoma: A Randomized Phase III Study of the EORTC Melanoma Group | |||||||||||||
Medical condition: Stage IV Metastatic Melanoma: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) GB (Prematurely Ended) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001243-30 | Sponsor Protocol Number: 840 30 40 | Start Date: 2004-12-09 | ||||||
Sponsor Name: Apogepha Arzneimittel GmbH | ||||||||
Full Title: Propiverine hydrochloride in children suffering from overactive bladder and urinary incontinence. A randomised, double-blind, placebo-controlled, parallel grouped multicentre clinical trial. | ||||||||
Medical condition: children suffering from overactive bladder and urinary incontinence | ||||||||
|
||||||||
Population Age: Children, Under 18 | Gender: Male, Female | |||||||
Trial protocol: CZ (Completed) SK (Completed) AT (Completed) SE (Completed) NL (Completed) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2004-003341-40 | Sponsor Protocol Number: PREEMPT 2005 | Start Date: 2004-12-08 | ||||||
Sponsor Name: University of Oxford | ||||||||
Full Title: PRE-EMPT: Prevention of Mood Disorders by Folic Acid Supplement. | ||||||||
Medical condition: Mood disorder | ||||||||
|
||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||
Trial protocol: GB (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2004-001511-54 | Sponsor Protocol Number: A5951060 | Start Date: 2004-12-08 | |||||||||||
Sponsor Name: Pfizer Global Research and Development | |||||||||||||
Full Title: Linezolid vs. Vancomycin/Oxacillin/Dicloxacillin in the Treatment of Catheter-Related Gram Positive Bloodstream Infections. | |||||||||||||
Medical condition: Catheter related gram positive bloodstream infection | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000763-98 | Sponsor Protocol Number: HP184B/2002 | Start Date: 2004-12-08 | ||||||
Sponsor Name: Aventis Pharmaceuticals Inc. | ||||||||
Full Title: A phase II, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of HP184 at 100, 200 and 400 mg doses administered orally once daily for twenty-four weeks in adult... | ||||||||
Medical condition: Chronic spinal cord injury | ||||||||
|
||||||||
Population Age: Adults | Gender: Male, Female | |||||||
Trial protocol: GB (Completed) DE (Completed) | ||||||||
Trial results: View results |